Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06223958 · ClinicalTrials.gov registry record · Phase 3
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (Axitinib Implant) in Subjects With Neovascular Age-Related Macular Degeneration
A Phase 3 study of Neovascular Age-related Macular Degeneration, sponsored by Ocular Therapeutix.
- Active
- Registry status
- Phase 3
- Development phase
- 344
- Enrollment target
- 20
- Study locations
NCT06223958 is a Phase 3 study of Neovascular Age-related Macular Degeneration that is active but no longer recruiting, run by Ocular Therapeutix. The registered enrollment target is 344 participants, below the 398-participant average among 33 other Neovascular Age-related Macular Degeneration trials with a reported enrollment target (14% lower). The trial reports 20 study locations across 2 states.
The verdict
NCT06223958, a Phase 3 study of Neovascular Age-related Macular Degeneration, is active but no longer recruiting, sponsored by Ocular Therapeutix.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 344 participants
- Enrollment target
- 20
- Study locations
Study Summary
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (axitinib implant) in Subjects with Neovascular Age-Related Macular Degeneration
Conditions Studied
Interventions
- DRUG Aflibercept
- DRUG OTX-TKI (axitinib implant)
Study Locations (20)
California
- CA CRC California Retina Consultants - Bakersfield
- The Retina Partners - Encino - Encino
- Retina Consultants of Orange County - Fullerton - Fullerton
- Atlantis Eyecare - Huntington Beach
- Lakeside Vision Center - Irvine - Irvine
- Retina-Vitreous Associates Medical Group - Los Angeles - Los Angeles
- CA RCMG Retinal Consultants Medical Group, Inc. - Modesto
- Retina Sacramento MSO, LLC - Modesto
- Kaiser Permanente Division of Research - Oakland
- CA CRC California Retina Consultants - Oxnard
- Stanford University School of Medicine, Byers Eye Institute - Palo Alto
- Doheny Eye Center - Pasadena
- AzulVision - Pasadena
- Orange County Retina Medical Group - Santa Ana
- California Retina Consultants (CRC) - Santa Barbara - Santa Barbara
- Macula Retina Vitreous Center - Torrance
Arizona
- Associated Retina Consultants - Gilbert - Gilbert
- Associated Retina Consultants - Phoenix - Phoenix
- Retinal Research Institute - Phoenix
- Retina Macula Institute of Arizona - Scottsdale
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 344 participants |
| Start Date | 2024-01-29 |
| Est. Completion | 2027-09-27 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06223958
The ClinicalTrials.gov registry entry for NCT06223958 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 344 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 398-participant average among 33 other Neovascular Age-related Macular Degeneration trials with a reported enrollment target (14% lower). The listed sponsor is Ocular Therapeutix, which has 20 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Neovascular Age-related Macular Degeneration appearing as the primary indexed condition, and to 2 interventions - of which Aflibercept is the first listed.
NCT06223958 reports 20 study locations spanning 2 distinct geographic areas - top geographies include California, Arizona.
Frequently Asked Questions
What is clinical trial NCT06223958 about?
NCT06223958 is a clinical study titled "Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (Axitinib Implant) in Subjects With Neovascular Age-Related Macular Degeneration". Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (axitinib implant) in Subjects with Neovascular Age-Related Macular Degeneration
What is the current status of trial NCT06223958?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 344 participants. The study started on 2024-01-29. Estimated completion is 2027-09-27.
What conditions does trial NCT06223958 study?
This clinical trial studies the following conditions: Neovascular Age-related Macular Degeneration.
What interventions are being tested in trial NCT06223958?
The interventions under investigation include: Aflibercept (DRUG), OTX-TKI (axitinib implant) (DRUG).
Who is sponsoring clinical trial NCT06223958?
This trial is sponsored by Ocular Therapeutix, which has 20 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06223958 being conducted?
This trial has 20 study locations across Arizona, California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Neovascular Age-related Macular Degeneration
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study to Assess the Injection Burden, Adverse Events, Change in Disease Activity, and Long-Term Preservation of Visual Acuity of Surabgene Lomparvovec in Adult Participants With Neovascular Age-Related Macular Degeneration (nAMD)
RECRUITING · Phase 3
-
Home OCT-Guided Treatment Versus Treat and Extend for the Management of Neovascular AMD
RECRUITING · Phase 3
-
Extension Study for the Port Delivery System With Ranibizumab (Portal)
RECRUITING · Phase 3
-
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Axitinib Implant) in Subjects With Neovascular Age- Related Macular Degeneration
ACTIVE NOT RECRUITING · Phase 3
-
A 3-month Study to Compare the Safety of ONS-5010 in Vials Versus Pre-filled Syringe in Subjects With Visual Impairment Due to Retinal Disorders
ACTIVE NOT RECRUITING · Phase 3
-
A Phase 3b, Single-Arm Study of Aflibercept 8 mg Dosed Every 4 Weeks in Adult Participants With Neovascular Age-Related Macular Degeneration (nAMD) or Diabetic Macular Edema (DME)
ACTIVE NOT RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.